A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery

NCT06583330 | Not Yet Recruiting

• 1 other identifier: BFH-VTE
• Study Type: interventional
• Target: 1,448
• Locations: 0 countries
• Sites: N/A

Brief Summary

research objective

1. 1.Optimize VTE prevention management after CRC surgery.
2. 2.Improve the prevention and treatment level of VTE in current perioperative patients.
3. 3.Reduce the social burden of VTE related diseases.
4. 4.start low molecular weight heparin prophylaxis within 24 hours post-surgery.
5. 5.The prophylactic regimen for the experimental group lasted 14 days, while the control group received it for 28 days. Low molecular weight heparin is given subcutaneously at a dose of 0.3ml once daily.
6. 6.atients underwent lower limb color Doppler ultrasound on postoperative days 7 ± 2, 14 ± 3, and 28 ± 5, which included screening for thrombosis in the proximal deep veins (femoral, popliteal), distal deep veins (posterior tibial, fibular, and muscular veins), and their perforating branches.

Conditions

Colorectal Surgery; VTE (Venous Thromboembolism)

Outcome Measures

Primary Outcomes (1)

• VTE events, including deep vein thrombosis (DVT) and pulmonary thromboembolism (PE).

  From enrollment to the end of treatment at 4 weeks

Study Arms (2)

experimental group

EXPERIMENTAL

Low molecular weight heparin should be initiated for drug prevention within 24 hours after surgery, with a preventive course of 14 days

Drug: Low Molecular Weight Heparin (dalteparin)

control arm

ACTIVE COMPARATOR

All patients should initiate low molecular weight heparin for drug prophylaxis within 24 hours after surgery, with a prophylaxis course of 28 days

Drug: Low Molecular Weight Heparin (dalteparin)

Interventions

Low Molecular Weight Heparin (dalteparin) DRUG

All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.

control arm; experimental group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age\>18 years old; Diagnosed with colorectal cancer and undergoing curative, palliative, or other limited surgeries (laparoscopic or open surgery), with an estimated surgery time of\>45 minutes; Expected postoperative survival\>6 months; Expected Caprini score of ≥ 5 on the first day after surgery; The patient agrees to the research plan and signs an informed consent form.

You may not qualify if:

• Renal dysfunction (CrCl\<30 mL/min) or liver dysfunction (ALT\>3 times the upper limit of normal); Known allergies to LMWH, anesthetics, or contrast agents; There is a systemic bleeding disorder or bleeding tendency, such as active peptic ulcer, uncontrolled hypertension, cerebral thrombosis within 6 months, cerebral hemorrhage, or a history of neurosurgical surgery; Known brain metastases, endocarditis, or previous heparin induced thrombocytopenia; VTE occurred within 3 months before surgery; Use heparin or oral anticoagulant therapy within 5 days before surgery; Pregnant or lactating women; Pregnant or lactating women; Any conditions that researcher determines the subject not suitable for anticoagulant therapy.

Sponsors & Collaborators

• Beijing Friendship Hospital: lead

MeSH Terms

Conditions

Venous Thromboembolism

Interventions

Heparin, Low-Molecular-Weight; Dalteparin

Condition Hierarchy (Ancestors)

Thromboembolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Heparin; Glycosaminoglycans; Polysaccharides; Carbohydrates

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 1, 2024
• First Posted: September 4, 2024
• Study Start: October 1, 2024
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: September 4, 2024

Record last verified: 2024-09